Formato Vancouver:
Chaparro M, Zanotti C, Burgueño P, Vera I, Bermejo F, Marín-Jiménez I et al. Health care costs of complex perianal fistula in Crohn's disease. Dig Dis Sci. 2013 Dec;58(12):3400-6.

PMID: 24026400

Contiene 24 referencias

To evaluate the use of health care resources and the associated costs of complex perianal Crohn's disease (CD) from the National Health System perspective. We conducted a multicenter, retrospective, observational study in which gastroenterologists from 11 hospitals in the Community of Madrid took part. Data was collected on the direct healthcare resources (pharmacological treatments, surgical procedures, laboratory/diagnostic tests, visits to specialists and emergency departments, and hospitalizations) consumed by 97 adult patients with complex perianal CD which was active at some point between January 1, 2005, and case history review. We recorded 527 treatments: 73.1 % pharmacological (32.3 % antibiotic, 20.5 % immunomodulator, 20.3 % biological) and 26.9 % surgical. Mean annual global cost was a,not sign8,289/patient, 75.3 % (a,not sign6,242) of which was accounted for by pharmacological treatments (a,not sign13.44 antibiotics; a,not sign1,136 immunomodulators; a,not sign5,093 biological agents), 12.4 % (a,not sign1,027) by hospitalizations and surgery, 7.7 % (a,not sign640) by medical visits, 4.2 % (a,not sign350) by laboratory/diagnostic tests, and 0.4 % (a,not sign30) by emergency department visits. Pharmacological therapies, and in particular biological agents, are the main cost driver in complex perianal CD; costs due to surgery and hospitalizations are much lower.